Klinikum Ludwigshafen, Ludwigshafen, Germany; Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.
Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Standort Berlin, Germany.
J Am Coll Cardiol. 2023 Mar 28;81(12):1165-1176. doi: 10.1016/j.jacc.2023.01.029.
Cardiac arrest (CA) is common in patients with infarct-related cardiogenic shock (CS).
The goal of this study was to identify the characteristics and outcomes of culprit lesion percutaneous coronary intervention (PCI) of patients with infarct-related CS stratified according to CA in the CULPRIT-SHOCK (Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock) randomized trial and registry.
Patients with CS with and without CA from the CULPRIT-SHOCK study were analyzed. All-cause death or severe renal failure leading to renal replacement therapy within 30 days and 1-year death were assessed.
Among 1,015 patients, 550 (54.2%) had CA. Patients with CA were younger, more frequently male, had lower rates of peripheral artery disease, a glomerular filtration rate <30 mL/min, and left main disease, and they presented more often with clinical signs of impaired organ perfusion. The composite of all-cause death or severe renal failure within 30 days occurred in 51.2% of patients with CA vs 48.5% in non-CA patients (P = 0.39) and 1-year death in 53.8% vs 50.4% (P = 0.29), respectively. In a multivariate analysis, CA was an independent predictor of 1-year mortality (HR: 1.27; 95% CI: 1.01-1.59). In the randomized trial, culprit lesion-only PCI was superior to immediate multivessel PCI in patients both with and without CA (P for interaction = 0.6).
More than 50% of patients with infarct-related CS had CA. These patients with CA were younger and had fewer comorbidities, but CA was an independent predictor of 1-year mortality. Culprit lesion-only PCI is the preferred strategy, both in patients with and without CA. (Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock [CULPRIT-SHOCK]; NCT01927549).
心搏骤停(CA)在与梗死相关的心源性休克(CS)患者中很常见。
本研究的目的是根据 CULPRIT-SHOCK(罪犯病变仅行经皮冠状动脉介入治疗与多血管病变经皮冠状动脉介入治疗在心源性休克中的比较)随机试验和登记研究中与 CS 相关的 CA 分层,确定与梗死相关 CS 患者的罪犯病变经皮冠状动脉介入治疗(PCI)的特征和结局。
分析了 CULPRIT-SHOCK 研究中伴有和不伴有 CA 的 CS 患者。评估了 30 天内全因死亡或导致肾脏替代治疗的严重肾功能衰竭以及 1 年死亡率。
在 1015 例患者中,550 例(54.2%)发生 CA。CA 患者更年轻,更多为男性,外周动脉疾病、肾小球滤过率<30mL/min 和左主干疾病的发生率较低,且更常出现器官灌注受损的临床征象。CA 患者 30 天内全因死亡或严重肾功能衰竭的复合终点发生率为 51.2%,而非 CA 患者为 48.5%(P=0.39),1 年死亡率分别为 53.8%和 50.4%(P=0.29)。多变量分析显示,CA 是 1 年死亡率的独立预测因素(HR:1.27;95%CI:1.01-1.59)。在随机试验中,对于伴有和不伴有 CA 的患者,罪犯病变仅 PCI 优于即刻多血管 PCI(P 交互=0.6)。
超过 50%的与梗死相关的 CS 患者发生 CA。这些 CA 患者更年轻,合并症更少,但 CA 是 1 年死亡率的独立预测因素。罪犯病变仅 PCI 是首选策略,无论患者是否伴有 CA。